Endometrial cancer is the most common gynaecological cancer in western countries, being the most common subtype of endometrioid tumours. Most patients are diagnosed at an early stage and present an excellent prognosis. However, a number of those continue to suffer recurrence, without means of identification by risk classification systems. Thus, finding a reliable marker to predict recurrence becomes an important unmet clinical issue. ALCAM is a cell-cell adhesion molecule and member of the immunoglobulin superfamily that has been associated with the genesis of many cancers. Here, we first determined the value of ALCAM as a marker of recurrence in endometrioid endometrial cancer by conducting a retrospective multicentre study of 174 primary tumours. In early-stage patients (N = 134), recurrence-free survival was poorer in patients with ALCAM-positive compared to ALCAM-negative tumours (HR 4.237; 95% CI 1.01-17.76). This difference was more significant in patients with early-stage moderately-poorly differentiated tumours (HR 9.259; 95% CI 2.12-53.47). In multivariate analysis, ALCAM positivity was an independent prognostic factor in early-stage disease (HR 6.027; 95% CI 1.41-25.74). Then we demonstrated in vitro a role for ALCAM in cell migration and invasion by using a loss-of-function model in two endometrial cancer cell lines. ALCAM depletion resulted in a reduced primary tumour size and reduced metastatic local spread in an orthotopic murine model. Gene expression analysis of ALCAM-depleted cell lines pointed to motility, invasiveness, cellular assembly, and organization as the most deregulated functions. Finally, we assessed some of the downstream effector genes that are involved in ALCAM-mediated cell migration; specifically FLNB, TXNRD1, and LAMC2 were validated at the mRNA and protein level. In conclusion, our results highlight the potential of ALCAM as a recurrent biomarker in early-stage endometrioid endometrial cancer and point to ALCAM as an important molecule in endometrial cancer dissemination by regulating cell migration, invasion, and metastasis.
Introduction
Endometrial cancer (EC) is the most common gynaecological cancer in western countries and the second leading cause of gynaecological malignancy worldwide [1] . Endometrial cancers are classified in two broad categories, endometrioid and non-endometrioid carcinoma, which are associated with different pathogeneses and prognoses [2] . Endometrioid endometrial cancers (EECs) comprise ≈ 80% of the tumours; present a better outcome; and manifest mainly a low-grade endometrioid histology, whereas non-endometrioid endometrial carcinomas (NEECs) are usually represented by serous carcinomas. While EECs are associated with a premalignant hyperplastic lesion and are related to hyperoestrogenism, NEECs are associated with atrophic endometrium and hormone-independent carcinomas [3] . Because abnormal vaginal bleeding is an early symptom of EC, around 75% of patients are diagnosed when the tumour is still confined to the uterus. These patients are classified in stage I, according to the Fédération International de Gynécologie et d'Obstétrique (FIGO), and present an excellent 5-year survival rate of ≈ 90% [4] . Even though those patients receive an optimal treatment according to their specific risk, a significant number of patients continue to present recurrence. This fact highlights an important unmet clinical need in the definition of more accurate risk stratification systems. Understanding the molecular processes associated with tumour dissemination may lead to the identification of predictive biomarkers, and thus improve the current risk classifications.
Cancer progression is a combination of multiple processes, in which cell adhesion molecules (CAMs) play a crucial role. Aberrant expression of CAMs contributes to loss of cell-cell adhesion, disaggregation of neoplastic cells from the lamina propia, extracellular matrix degradation, and activation of processes in invasion and migration [5] . Among CAMs, the function of cadherins or integrins has been deeply studied in cancer metastasis but remarkably, the immunoglubulin superfamily (IgSF) has received less attention [6] .
Activated leukocyte cell adhesion molecule (ALCAM) is a 105 kDa transmembrane glycoprotein that belongs to the IgSF. It is a cell-cell adhesion molecule that participates either in homotypic (ALCAM-ALCAM) or in heterotypic (ALCAM-CD6) interactions between adjacent cells [7] . ALCAM is widely distributed within tissues and is reported to function in extensive biological processes including neuronal outgrowth, inflammatory responses, haematopoiesis, and epithelial morphogenesis [8] . In recent years, ALCAM has been associated with tumourigenesis of many cancers [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In those, the potential use of ALCAM as a biomarker of recurrence was raised but it was linked to contradictory results, greatly limiting its value to predict a clinical outcome. In fact, even for the same type of malignancy, ALCAM has been described as a marker of good prognosis, of poor prognosis, or even completely unrelated to survival [19] .
In this work, we conducted a retrospective multicentre study to evaluate the immunohistochemical expression of ALCAM in EEC primary tumour tissues as a reliable marker of recurrence. In addition, we used in vitro studies and an in vivo orthotopic murine model, which highlighted the functions regulated by ALCAM that promote EC dissemination and metastasis.
Materials and methods

Human endometrial cancer samples
For the 10-year retrospective multicentre study, a total of 174 EEC formalin-fixed, paraffin-embedded tissue samples were recruited from Vall d'Hebron Hospital (Barcelona, Spain), Arnau de Vilanova Hospital (Lleida, Spain), Hospital del Mar (Barcelona, Spain), University Hospital of Santiago de Compostela (Santiago de Compostela, Spain), MD Anderson Cancer Center Madrid (Madrid, Spain), and Virgen del Rocio Hospital (Seville, Spain). The Ethics Committee of each institution approved this study. The clinicopathological parameters of these patients are described in Table S1 (supplementary material).
ALCAM immunostaining in EC patients
Tissue microarrays (TMAs) and immunohistochemistry were performed as described in ref 20 . Indirect immunoperoxidase staining assay was performed following antigen retrieval in citrate buffer at pH 9. Sections were incubated with primary antibody for 1 h at room temperature using 1:100 mAb ALCAM (MOG/07; Abcam, Cambridge, MA, USA). A pathologist evaluated ALCAM expression using two criteria: an intensity score (ranging from 1 to 3) and the percentage of positive staining cells. The product of the two assessments yielded final values on a scale ranging from 0 to 300. The cut-off for the dichotomization was set to ≥30, corresponding to the first quartile of the distribution of the ALCAM expression value in the cohort. 
Western blot and protein cell extraction
Western blot was performed as described in ref 21 . Cell lysates were obtained using RIPA buffer and PhosphoStop 1× (Roche, Basel, Switzerland), incubated at 4 ∘ C for 1 h, and passed through a syringe for cell disruption; proteins were separated by gel electrophoresis and then transferred onto a PVDF membrane. The antibodies used are described in the supplementary material, Supplementary materials and methods.
Reverse transcription-quantitative PCR (RT-qPCR)
RNA was extracted with an RNeasy Mini kit (Qiagen, CA, USA), reverse transcribed with SuperScript III (Invitrogen, Carlsbad, CA, USA), and analysed by real-time qPCR following the manufacturer's protocol (Roche). SYBR ® Green primers are listed in Table S2 (supplementary material). Fold change (FC) in expression was calculated using the ddCT method. Data were normalized to GAPDH.
Wound healing assay
A total of 5-8 × 10 5 cells were seeded into 24-well plates and cultured until confluence. A wound was made by scraping the cell monolayer with a 10 μl pipette tip. Images were captured at 0, 24, and 48 h using an FSX100 inverted microscope (Olympus, Hamburg, Germany) to measure the wound closure rate.
Transwell invasion assay
A total of 5 × 10 5 cells were seeded on 8 μm pore size Transwell filters of the CytoSelect 24-well cell invasion assay kit (Cell Biolabs, San Diego, CA, USA) and allowed to invade for 36-48 h. Cells were stained with DAPI and phalloidin and counted with Image J (National Institutes of Health, Bethesda, MD, USA).
Measurement of the separation force (SF) between cells
We used a micromanipulation technique described previously [22] . In brief, isolated cells were manipulated at 37 ∘ C with two micropipettes, each held by one micromanipulator connected to a combined hydraulic/pneumatic system and a pressure sensor making it possible to control and measure the aspiration applied to the cells. A pressure sensor measured the aspiration applied to the left pipette. Aspiration was monitored continuously during the separation process, and the values recorded for each of the last two cycles in the series (Pn-1 and Pn) were used to calculate the separation force (SF) for each doublet using the equation SF = π (d/2) 2 (Pn-1 + Pn)/2, where d is the inside diameter of the left pipette. The results for 15-40 measurements were used to obtain the mean force of separation for a specific contact time.
Aggregate spreading
As described in ref 23 , aggregates were deposited randomly on fibronectin-coated coverslips in a magnetic imaging chamber (Chamlide CMB, CM-B25-1; Quorum Technologies, Guelph, Ontario, Canada) filled with CO 2 -equilibrated culture medium. Spreading was observed using a Nikon confocal microscope equipped with a × 10 air objective and a 37 ∘ C heating cube system. Bright field images were recorded with a CCD camera (Luca-R; Andor, Belfast, Northern Ireland, UK) using NIS-Elements software. The area of each aggregate was measured with Image J software at 48 h (National Institutes of Health, Bethesda). Aggregate and coating preparation may be found in the supplementary material, Supplementary materials and methods.
Cell growth/viability assay
A total of 4000 cells per well were seeded into 96-well plates. Cell viability was measured after 0, 24, 48, 72, 96, and 120 h. Cells were stained with crystal violet (0.5%, dissolved in 15% acetic acid) and the absorbance of the supernatant was read at 595 nm.
Propidium iodide DNA staining
After 48 h, a total of 1 × 10 6 cells were trypsinized, resuspended in 300 μl of PBS, and fixed with 700 μl of pre-cooled EtOH for 2 h on ice. Cells were pelleted (5000 rpm); resuspended in 38 nM sodium citrate, 500 μg/ml propidium iodide, 10 mg/ml RNAse A; and analysed by flow cytometry.
Orthotopic murine model
All the procedures were performed according to the guidelines of the Spanish Council for Animal Care and the institutional guidelines for animal welfare (CEEA 23/16). A total of 24 6-week-old female athymic nude mice (Charles River Laboratories, Inc, Wilmington, MA, USA) were inoculated by transmyometrial injection of stably transfected Hec1A shControl and Hec1A shALCAM2 cells (n = 12 per group) as described in ref 24 . Mice were sacrificed 7 weeks after the injection. Tumour growth and dissemination were evaluated macroscopically and histologically ex vivo. For histological analysis, all extracted tissues were formalin-fixed, stained with haematoxylin and eosin (H&E), and evaluated by a pathologist. Ki67 expression was scored using the ACIS ® III Instrument automated imaging system (Dako, Glostrup, Denmark).
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Microarray analysis: Illumina HumanHT-12 v4
Triplicates of Hec1A shControl and Hec1A shAL-CAM1 were used to perform this study. A description of the microarray analysis is given in the supplementary material, Supplementary materials and methods. For the detection of differentially expressed genes, a linear model was fitted to the corrected, transformed, and normalized data, and empirical Bayes moderated t-statistics were calculated using the limma package from Bioconductor. Adjustment of p-values was done by the determination of false discovery rates (FDRs) using the Benjami-Hochberg procedure. Microarray data have been deposited in NCBI's Gene Expression Omnibus (Devis et al, 2016) and are accessible through GEO Series accession number GSE86543 (https://www .ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86543). For the gene ontology analysis, deregulated genes with a fold change greater than 1.2 and an adjusted p value less than 0.05 were introduced in the PANTHER database [25] and in QIAGEN'S Ingenuity ® Pathway Analysis (IPA ® QIAGEN, Redwood City, CA, USA; http://www .ingenuity.com/).
Statistical analysis
For categorical variables: the relationship between ALCAM expression and clinicopathological parameters was tested in univariate analysis by chi-square and Fisher's exact test, two-sided p-values. Stratified analysis was performed to study the relationship between the recurrence and the ALCAM status. Follow-up studies were analysed by Kaplan-Meier and Cox's proportional hazards test. Recurrence-free survival was evaluated in the present study but not overall survival, as the number of deaths from disease did not allow a reliable statistical analysis.
For continuous variables: the normal distribution of data was verified (Shapiro-Wilk test) and accordingly parametric [t-test, ANOVA, and multiple post hoc comparisons (Scheffe, Dunnet)] and non-parametric (Mann-Whitney) tests were performed for each comparison. Measurements were made in triplicates in three independent experiments and presented with the mean ± SD (exceptions are specified in the figure legends).
Statistical analyses were performed using IBM SPSS Statistics 21. All p-values less than 0.05 were considered statistically significant.
Results
ALCAM-positive expression is a marker of recurrence in early-stage moderately-poorly differentiated tumours
Among the 174 EEC patients analysed for ALCAM expression, we found 131 (76.20%) to be ALCAM-positive (supplementary material, Table S3 ). Expression of ALCAM was homogeneous across the section and predominantly localized at the membrane and cytoplasm (supplementary material, Figure S1D ). Of the included cancers, 77.9% were early-stage EEC (stages IA and IB of the FIGO classification), containing 88 well-differentiated (GI) and 45 moderately-poorly differentiated tumours (GII-GIII), whereas the 22.1% of remaining cases were diagnosed at advanced stages. The univariate analysis between ALCAM expression and the most common prognostic factors showed a minor correlation only with tumour grade when studied in the whole population (supplementary material, Table S3 ). Interestingly, in a stratified analysis, ALCAM expression showed a significant correlation to the recurrence for patients diagnosed at early stage (N = 134) (p = 0.039) with moderately-poorly differentiated tumours (N = 80) (p = 0.007) and with tumours combining these two clinical parameters (N = 45) (p = 0.012) ( Table 1) . Specifically, in the subset of patients diagnosed at early stage, the recurrence rate was significantly higher for ALCAM-positive patients than for ALCAM-negative patients (27.8% versus 7.7%). The results were similar for patients with moderately-poorly differentiated tumours (59.2% versus 25.0%), and noteworthy for the early-stage moderately-poorly differentiated cohort, in which the percentage of ALCAM positivity in recurrent patients increased up to 55.9% compared with 9.1% for ALCAM-negative patients (supplementary material, Figure S1A-D) .
These results were supported by univariate Cox regression and Kaplan-Meier analyses. Recurrencefree survival was poorer in patients with Figure 1A) . Similarly, for patients with moderately-poorly differentiated tumours, recurrence-free survival was 93.243 versus 64.762 months (p = 0.011), with an HR of 2.966 (p = 0.016) ( Figure 1B) . Again, the largest difference was observed in patients with early-stage moderately-poorly differentiated tumours, in which ALCAM reached an HR of 9.259 (p = 0.034). In this sub-cohort, recurrence-free survival was significantly longer in ALCAM-negative cancers than in patients with ALCAM-positive expression (110.636 versus 68.279 months, respectively) ( Figure 1C ). Furthermore, in the early-stage patients, ALCAM positivity was identified as an independent prognostic factor of recurrence, with an HR of 6.027 (p = 0.015), together with tumour grade, with an HR of 5.634 (p < 0.001), in a multivariate Cox regression analysis ( Table 2) .
Inhibition of ALCAM in EEC cell lines decreases cell migration, invasion, and cell-cell adhesion
To understand the role of ALCAM in endometrial tumour progression and dissemination, we studied the effect of ALCAM inhibition in Hec1A EEC cells. We generated two ALCAM-depleted Hec1A cell lines by using two shRNAs, obtaining more than 70% of inhibition (Figure 2A, B) . We used in vitro 2D and 3D models to evaluate the role of ALCAM in EEC motility and a dual micropipette assay to determine quantitatively ALCAM function in cell-cell adhesion. ALCAM depletion decreased the wound closure rate of Hec1A cells in a 2D wound healing assay ( Figure 2C ). To mimic tumour progression in patients, we used a 3D model to quantitatively study the spreading of cell aggregates with ALCAM depletion on a fibronectin-coated surface. Three-dimensional models fill the gap between 2D cell cultures and animal systems as they mimic characteristics of the in vivo environment [26] . Specifically, this model leads to the study of the competition between cell-cell and cell-substratum adhesion on tissue spreading [27] . We found that, in agreement with 2D studies, ALCAM-depleted cells presented decreased motility in the 3D model ( Figure 2D ). In addition, ALCAM-depleted cells showed significantly reduced invasive capability on a Matrigel Transwell assay ( Figure 2E ).
Finally, we evaluated how ALCAM affects the formation and strength of cell-cell adhesion. Two isolated cells maintained in suspension, to avoid cell-matrix interactions, were put into contact to initiate adhesion by using two micropipettes. After a defined period of contact, we measured the forces required to separate them. The mean SF is used as readout of the strength of adhesion for a specific contact time. In both control and ALCAM-depleted cells, the SF required to disrupt the cell doublet increased with the time of contact. However, at all time points, intercellular cell adhesion was weaker in the ALCAM-depleted cells (Figure 2 F) . Cell-cell adhesion and aggregate spheroid assays indicated ALCAM as an important player in the overall balance of adhesion, which is crucial in cancer processes. Those effects were independent of cell proliferation, as no significant differences were seen in cell viability or progression through the cell cycle ( Figure 2G, H) .
The same results were observed with the ALCAM-depleted Ishikawa EEC cell line (see supplementary material, Figure S2A, B) . Specifically, Ishikawa shALCAM cells presented a lower rate of wound closure and decreased invasive ability, and no differences in cell proliferation were observed (see supplementary material, Figure S2C-F) . Taken together, these results support the role of ALCAM in key processes for tumour dissemination, leading to less aggressive phenotypes when suppressed.
Depletion of ALCAM affects primary tumour size and inhibits metastasis in an orthotopic murine model of EEC
To assess the effect of ALCAM on tumour development and metastasis, we used a clinically relevant EEC orthotopic murine model. We inoculated stably transfected control or ALCAM-depleted cells into the uteri of mice and after 7 weeks, both conditions developed solid tumours ( Figure 3A ). Hec1A shControl tumours were larger than those generated by shALCAM cells (Figure 3B, C) . However, no differences were observed in H&E or Ki67 staining ( Figure 3A ; p = 0.3), indicating that the dissimilarity in tumour size was not due to cell proliferation. These results might indicate that ALCAM interferes with the ability of tumour cells to communicate with the surrounding microenvironment. Reinforcing this hypothesis, mice with ALCAM-depleted cells developed fewer metastases and, more significantly, fewer local metastases than the control ( Figure 3D , E). Local metastases were differentially found in the peritoneum, pelvic fat, kidney, spleen, pancreas, colon, liver, and diaphragm (Figure 3 F) . Accordingly, we observed that a larger proportion of control mice presented macrometastases (>5 mm) ( Figure 3G, H) . Taken together, these results show that ALCAM depletion profoundly affects the ability of tumour cells to develop metastasis.
Microarray analysis of ALCAM-dependent gene expression in the Hec1A cell line
To elucidate the molecular mechanisms governed by ALCAM to promote EC dissemination and metastasis, we performed a cDNA microarray to compare the gene expression profiles of Hec1A shControl and shALCAM cells. A total of 315 genes were found to be deregulated, with FC > 1.2 and adjusted p value less than 0.05. Of those, a heat map of the 50 most significant deregulated genes is shown in Figure 4A . All of the differentially expressed genes were identified in IPA and PANTHER databases for gene ontology analysis. We found that the deregulated genes were related to commonly altered pathways in cancer ( Figure 4B ) and among those, the integrin signalling pathway was the most significantly altered ( Figure 4C ). The IPA analysis revealed that the most enriched functions corresponded to cell movement, cell migration, and cell invasion. We also observed that ALCAM inhibition had an effect on cellular assembly and organization through the regulation of genes involved in the formation of cellular protrusions, microtubule dynamics, organization of the cytoplasm and cytoskeleton, among others, as well as functions related to cell-cell adhesion ( Figure 4D ). All of them presented a negative z-score and thus are predicted to be inhibited in ALCAM-depleted cells, in agreement with our previous observations.
ALCAM regulates LAMC2, FLNB, and TXNRD1 during EEC dissemination
To characterize the downstream effectors of ALCAMmediated functions, we selected from the microarray data the most deregulated genes (FC > 1.4; adjusted p < 0.05) related to the cell motility, cell movement, and cell invasion functions. Additionally, genes from the plasminogen activating cascade, which participated in the same functions, were included (Table 3 ). The levels of 21 mRNAs were validated by RT-qPCR, using both knockdown and Hec1A-ALCAM-overexpressing cells. Among those, six genes -LAMC2, TXNRD1, FLNB, EPHA2, PLAU, and KLK6 -presented coherent behaviour in ALCAM-depleted and ALCAM-overexpressing cells ( Figure 5A and supplementary material, Figure  S3A , B). LAMC2, TXNRD1, and FLNB also showed decreased protein levels in ALCAM-depleted cells ( Figure 5B ). This finding supported their role as downstream effectors of the ALCAM-related functions.
Discussion
The main goal of risk stratification systems in EC is to identify those patients who will benefit from a specific adjuvant treatment. A general consensus was recently reached between the European Society for Medical Oncology, the European Society for Radiotherapy and Oncology, and the European Society of Gynaecological Oncology to define recurrence risk groups based on the assessment of prognostic factors: age, FIGO stage, grade, and histology [28] . Following this classification, EEC patients at low and intermediate risk of recurrence achieve an overall 5-year survival rate of ≈ 90%. Nonetheless, a significant number of patients stratified according to these clinicopathological parameters experience recurrence and die from the disease. In this multicentre retrospective study, ALCAM expression was associated with an increase in recurrence and was an independent factor of prognosis in early-stage EEC patients. Moreover, ALCAM-positive expression was correlated with a decrease in recurrence-free survival, reaching an HR Recent studies have also identified other markers, such as L1CAM [29] and ANXA2 [30] , which improved risk prediction in early-stage EEC. Actually, L1CAM also belongs to the IgSF, adding weight to the role of CAMs in EC dissemination and metastasis. Further validations are needed in order to foster the implementation of ALCAM and other markers in new risk prediction models that may favourably impact on the survival of EC patients.
CAMs are essential for cell attachment, tissue organization, and development, and also play a major role in transmembrane signalling and cell motility. Interaction of cadherins, integrins, selectins, and IgSF members results in signal transduction into the cell [31] . In fact, they translate external mechanical forces through the cytoskeleton to activate biochemical signals within the cell [32] . ALCAM homotypic adhesion is a tightly regulated process and has been associated with cell motility and metastasis in cancer [33] . ALCAM has been described to interact with the actin cytoskeleton, as a low concentration of cytochalasin D allowed partial disruption of the cytoskeleton, this being necessary for the transient ALCAM release from the actin cortex and for the stable homotypic ALCAM-mediated adhesion [34] . Actually, ALCAM is composed of five extracellular domains, a transmembrane region, and a short cytoplasmic tail that can interact, via adaptor proteins, with the actin cytoskeleton [35] . The cytoplasmic tail includes a positive-charge-rich domain (PCRD) and a PDZ-binding motif, KTEA, at the C-terminus [36] . The existence of a supramolecular complex has been demonstrated, wherein ALCAM binds to syntenin-1 and ezrin, allowing ALCAM to interact with the actin [37] . In addition, PKCα also plays a role in the cytoskeleton-dependent avidity modulation of ALCAM [34] and regulates the supramolecular complex formed by ALCAM-ezrin [36] . In our study, less force was required to separate ALCAM-depleted cells, demonstrating its role in cell-cell adhesion. As such, several studies have evidenced crosstalk between cell-cell and cell-matrix adhesion in regulating cell migration [38, 39] . ALCAM modulation may have impacted the balance between cell-cell and cell-matrix adhesion with an effect on cell polarization and migration. We also demonstrated that ALCAM acted as a positive regulator of migration and invasion in Hec1A and Ishikawa cells. Moreover, we tested the tumourigenic and metastatic abilities of ALCAM-depleted cells in vivo in an EC orthotopic murine model. We found that ALCAM inhibition decreased both the size of the primary tumour and the number of metastases. Specifically, ALCAM inhibition impaired the ability of tumour cells to disseminate at the locoregional level. These results were independent of an increase in cell proliferation and lead us to speculate that ALCAM depletion interferes with the ability of tumour cells to communicate with the surrounding microenvironment. Similarly, ALCAM knockdown in malignant mesothelioma cells was related to suppressed migration and invasion [40] . Moreover, Wiiger et al used a fully human scFv antibody recognizing ALCAM on cancer cells that reduced cell invasion [41] .
Microarray analysis showed an enrichment of deregulated genes involved in cell migration and invasion. Microarray validation by RT-qPCR and western blot demonstrated that FLNB, TXNRD1, and LAMC2 are dependent on ALCAM regulation, so we hypothesize that those proteins may be downstream effectors of ALCAM-mediated functions. Filamins are a type of actin-binding proteins that play an important role in cross-linking cortical actin filament in 3D structures. They have been reported to interact directly with many functional proteins [42, 43] , including channels, IgSF members, integrins, kinases, and transcription factors. FLNB has been described to promote cancer cells' invasiveness and a spindle-shaped morphology [44] . Iguchi et al [44] proposed a model whereby FLNB enhances contractile forces generated by actomyosin via regulation of the dephosphorylation of the myosin regulatory light chain. They also state that FLNB may be responsible for promoting invasion through FAK-mediated regulation of focal adhesion turnover. In this scenario, it is tempting to hypothesize that FLNB could bind to the ALCAM cytoplasmic tail and serve as a scaffold for ALCAM-mediated functions into the cell.
Additionally, TXNRD1 possesses glutaredoxin-and thioredoxin-reductase activity. Moreover, specific functions of TXNRD1 splice variants have been described to regulate the cell cytoskeleton by the induction of actin and tubulin polymerization, this leading to the basement membrane [47] . LAMC2 expression has been correlated with clinical outcome and metastatic potential in different cancers [48] [49] [50] . The exact mechanisms leading to ALCAM regulation of TXNRD1 and LAMC2 remain unclear and should be further studied in future work.
In summary, we have demonstrated the clinical utility of ALCAM expression as a biomarker of recurrence in early-stage moderately-poorly differentiated EEC tumours. We have established the role of ALCAM as a positive modulator of cell adhesion, motility, and invasiveness, in vitro and in vivo, and have identified some of the downstream effector genes that are involved in ALCAM-mediated cell functions, specifically FLNB, TXNRD1, and LAMC2. Taken together, our results point to ALCAM as an important molecule in EC carcinogenesis and metastasis development, and suggest that identifying the intrinsic mechanisms in which it is involved may lead to the development of powerful clinical and therapeutic approaches. Figure S1 . ALCAM positivity is a marker for recurrence Figure S2 . Inhibition of ALCAM in the Ishikawa cell line decreases cell migration and invasion in vitro Figure S3 . RT-qPCR performed on deregulated genes from the microarray study Table S1 . Tissue microarray patient variables Table S2 . Primers designed for SYBR Green RT-qPCR To view these articles, and more, please visit: www.thejournalofpathology.com
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